Q-omics provides the consensus-scored DNAI1 profile across patient tissues and cancer cell-line models. DNAI1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DNAI1 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, DNAI1 RNA expression shows 15,871 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, KICH, and KIRP as cancer lineages where DNAI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAI1 survival associations across molecular data types. DNAI1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAI1 RNA expression–survival associations across cancer types. High DNAI1 expression shows unfavorable associations in COAD and LIHC, but favorable associations in UVM, ACC, PAAD and CESC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for DNAI1 RNA expression.
This table summarizes DNAI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DNAI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAI1 shows lower tumor expression in KICH, KIRC, LUSC and LUAD and higher tumor expression in KIRP and BRCA. The KICH box plot shows higher DNAI1 RNA expression in normal versus tumor tissue (log2 FC = −1.017, t-test p < 0.001).
This table shows molecular features associated with DNAI1 in patient tissues and cancer cell lines. In patient samples, DNAI1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
